ClinicalTrials.gg
CompletedNCT02963077Updated Mar 7, 2024

A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384

A Phase 1 interventional study of A4250 and CRC (A3384) in Orphan Cholestatic Liver Diseases, Primary Biliary Cirrhosis and Progressive Familial Intrahepatic Cholestasis, sponsored by Albireo. Completed. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-07.

Sponsored by Albireo (part of Ipsen) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Liver Cirrhosis, Biliary by Ipsen — 3 open to participants now, 6 under way, 3 of them phase 3. Liver Cirrhosis, Biliary · Ipsen.

Started
2013
the only one that year
Phase 1
2 of 10
none open now
Registered
1st of 10
by date

Among the 10 studies in Liver Cirrhosis, Biliary by Ipsen, this one is the only one that started in 2013, is one of 2 in phase 1, and was the 1st registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

3 of the 10 studies in Liver Cirrhosis, Biliary by Ipsen are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Liver Cirrhosis, Biliary by Ipsen, or all of them as a file.
02

Study summary

The primary objectives of the study are to evaluate the safety, tolerability and pharmacokinetics of A4250 after single or multiple oral doses in healthy subjects. In addition, will evaluate A4250 in combination with cholestyramine.

03

Conditions studied

  • Orphan Cholestatic Liver Diseases
  • Primary Biliary Cirrhosis
  • Progressive Familial Intrahepatic Cholestasis
  • Alagille Syndrome
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males or non-pregnant, non-lactating healthy females
  2. of 18 to 32 kg/m2 or, if outside the range, considered not by the investigator
  3. Willing and able to communicate and participate in the whole study
  4. Provided written
  5. Agreed to use an adequate method of

Exclusion criteria

Exclusion Criteria:

  1. Had participated in a clinical research study within the previous 3 months
  2. Were study site employees, or immediate family members of a study site or sponsor employee
  3. Had previously been enrolled in this study
  4. History of any drug or alcohol abuse in the past 2 years
  5. Regular alcohol consumption, in males >21 units per week and females >14 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)
  6. Current smokers and those who had smoked within the last 12 months. A breath carbon monoxide (CO) reading of greater than 10 ppm at screening
  7. Females of who were pregnant or lactating (female subjects must have had a negative urine pregnancy test at admission)
  8. Did not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening
  9. abnormal biochemistry, haematology or urinalysis as judged by the investigator
  10. Positive drugs of abuse test result
  11. Positive surface antigen (HBsAg), virus antibody (HCV Ab) or (HIV) results
  12. History of cardiovascular, renal, hepatic, chronic respiratory or GI disease as judged by the investigator
  13. Serious adverse reaction or serious to any drug or the formulation eg lactose or to cholestyramine/Questran
  14. Presence or history of clinically significant allergy requiring treatment as per the judgement of the investigator Hayfever was allowed unless it was active
  15. Donation or loss of greater than 400 mL of blood within the previous 3 months
  16. Were taking, or had taken, any prescribed or over-the-counter drug (other than up to 4 g per day paracetamol, hormone replacement therapy [HRT] and hormonal ) or herbal remedies in the 14 days before IMP administration unless they were not considered to have interfered with the objectives of the study, as agreed by the PI and sponsor's medical monitor on a case by case basis
  17. Failed to satisfy the investigator of fitness to participate for any other reason
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    Cohort 1 SAD - 0.1 mg A4250

    Dose: 0.1 mg of A4250. Sentinel dosing was used (2 sub-cohorts dosed a minimum of 24 h apart).

    Drug: A4250

  • Experimental
    Cohort 2 SAD - 0.3 mg A4250

    Dose: 0.3 mg of A4250.

    Drug: A4250

  • Experimental
    Cohort 3 SAD - 1 mg A4250

    Dose: 1 mg A4250.

    Drug: A4250

  • Experimental
    Cohort 4 SAD - 3 mg A4250

    Dose: 3 mg A4250.

    Drug: A4250

  • Experimental
    Cohort 5 SAD - 10 mg A4250

    Dose: 10 mg A4250.

    Drug: A4250

  • Placebo comparator
    Cohort 1 SAD placebo

    Dose: 0.1 mg of A4250 matching placebo. Sentinel dosing was used (2 sub-cohorts dosed a minimum of 24 h apart).

    Drug: Placebo

  • Placebo comparator
    Cohort 2 SAD placebo

    Dose: 0.3 mg A4250 matching placebo.

    Drug: Placebo

  • Placebo comparator
    Cohort 3 SAD placebo

    Dose: 1 mg A4250 matching placebo.

    Drug: Placebo

  • Placebo comparator
    Cohort 4 SAD placebo

    Dose: 3 mg A4250 matching placebo.

    Drug: Placebo

  • Placebo comparator
    Cohort 5 SAD placebo

    Dose: 10 mg A4250 matching placebo.

    Drug: Placebo

  • Experimental
    Cohort 1 MAD - 1 mg A4250 qd

    Dose: 1 mg A4250 qd for 7 days.

    Drug: A4250

  • Placebo comparator
    Cohort 1 MAD placebo

    Dose: 1 mg A4250 matching placebo qd for 7 days.

    Drug: Placebo

  • Experimental
    Cohort 2 MAD - 3 mg A4250

    Dose: 3 mg A4250 qd for 7 days

    Drug: A4250

  • Placebo comparator
    Cohort 2 MAD placebo

    Dose: 3 mg A4250 matching placebo qd for 7 days.

    Drug: Placebo

  • Experimental
    Cohort 3 MAD - 1.5 mg A4250 b.i.d for 7 days.

    Dose: 1.5 mg A4250 b.i.d. for 7 days.

    Drug: A4250

  • Placebo comparator
    Cohort 3 MAD placebo

    Dose: 1.5 A4250 matching placebo b.i.d for 7 days.

    Drug: Placebo

  • Experimental
    Cohort 4 MAD - 3 mg A4250 qd + 1 mg Questran b.i.d

    Dose: 3 mg A4250 qd + 1 mg Questran b.i.d for 7 days.

    Drug: A4250 · Drug: Questran

  • Active comparator
    Cohort 4 MAD A4250 placebo + 1 mg Questran b.i.d

    Dose: 3 mg A4250 matching placebo + 1 mg Questran b.i.d for 7 days.

    Drug: Questran · Drug: Placebo

  • Experimental
    Cohort 5 MAD - 3 mg A4250 qd + 1 g CRC b.i.d

    Dose: 3 mg A4250 qd + 1 g CRC b.i.d for 7 days.

    Drug: A4250 · Drug: CRC (A3384)

  • Placebo comparator
    Cohort 5 MAD A4250 placebo + CRC placebo

    Dose: 3 mg A4250 matching placebo qd + 1 g CRC placebo b.i.d for 7 days

    Drug: Placebo

  • Active comparator
    Cohort 6 MAD - 1 g CRC

    Dose: 1 g CRC b.i.d

    Drug: CRC (A3384)

  • Placebo comparator
    Cohort 6 MAD CRC placebo

    Dose: 1 g CRC matching placebo b.i.d.

    Drug: Placebo

  • Experimental
    Cohort 7 MAD - 3 mg A4250 qd + 1 g CRC b.i.d

    Dose: 3 mg A4250 qd + 1 g CRC b.i.d

    Drug: A4250 · Drug: CRC (A3384)

  • Placebo comparator
    Cohort 7 MAD A4250 placebo + CRC placebo

    Dose: 3 mg A4250 matching placebo qd + 1 g CRC matching placebo b.i.d.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean (± SD) Plasma Pharmacokinetic Concentrations of A4250 Following A Single Oral 10 mg A4250 Dose - Tmax

    Time frame: Pharmacokinetic blood samples were taken pre-dose, and post-dose at: 0.5 hour, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours

  2. Mean (± SD) Plasma Pharmacokinetic Concentrations of A4250 Following a Single Oral 10 mg A4250 Dose - Cmax

    Time frame: Pharmacokinetic blood samples were taken pre-dose, and post-dose at: 0.5 hour, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours

  3. Mean (± SD) Plasma Pharmacokinetic Concentrations of A4250 Following a Single Oral 10 mg A4250 Dose - AUC 0-t

    Time frame: Pharmacokinetic blood samples were taken pre-dose, and post-dose at: 0.5 hour, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours

  4. Mean (SD) Change in FGF19 from Day 1 Pre-Dose to 4 h Post-Dose

    Time frame: Pharmacodynamic blood samples were taken pre-dose and at 4 hours and 24 hours post-dosing, and at follow-up (5-7 days after final dose).

  5. Mean (SD) Change in FGF19 from Day 1 Pre-Dose to 24 h Post-Dose

    Time frame: Pharmacodynamic blood samples were taken pre-dose and at 4 hours and 24 hours post-dosing, and at follow-up (5-7 days after final dose).

  6. Mean (SD) Change in C4 from Day 1 Pre-Dose to 4 h Post-Dose

    Time frame: Pharmacodynamic blood samples were taken pre-dose and at 4 hours and 24 hours post-dosing, and at follow-up (5-7 days after final dose).

  7. Mean (SD) Change in C4 from Day 1 Pre-Dose to 24 h Post-Dose

    Time frame: Pharmacodynamic blood samples were taken pre-dose and at 4 hours and 24 hours post-dosing, and at follow-up (5-7 days after final dose).

  8. Mean (SD) Changes in Total Bile Acids for A4250 4 h compared to pre-dose

    Time frame: Samples were taken pre-dose and post-dose at 4 hours and 24 hours.

  9. Mean (SD) Changes in Total Bile Acids for A4250 24 h compared to pre-dose

    Time frame: Samples were taken pre-dose, and post-dose at 4 hours and 24 hours.

  10. Geometric (geometric CV%) Mean for AUC(0-12) on Day 7 for plasma FGF19

    Time frame: AUC(0-12) on Day 7 (only for Part II)

  11. Geometric (geometric CV%) Mean for AUC(0-12) on Day 7 for plasma C4

    Time frame: AUC(0-12) on Day 7 (only Part II)

  12. Geometric (geometric CV%) Mean for AUC(0-12) on Day 7 for plasma Total Bile Acids

    Time frame: AUC(0-12) on Day 7 (only Part II)

  13. Mean (SD) Changes in Faecel Total Bile Acids from Day 1 Pre-Dose on Day 7 at 24 h Post-dose

    Time frame: Change from Day 1 Pre-dose to Day 7 at 24 hours Post-dose

  14. Mean (SD) Change in Faecal Total Bile Acids Excreted (ng) from Day 1 Pre-Dose on Day 7 Post-Dose

    Time frame: Change from Day 1 Pre-dose to Day 7 at 24 hours Post-dose

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2016
First posted
Nov 15, 2016
Start
Jul 2013
Primary completionActual
May 2014
CompletionActual
May 2014
Last update
Mar 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02963077
Lead sponsor
Albireo
Responsible party
Sponsor
First posted
Nov 15, 2016
Start date
Jul 2013
Primary completion
May 2014
Completion
May 2014
Last update
Mar 7, 2024

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Odevixibat · Cholestyramine Resin

Start the discussion